terraplasma medical

What terraplasma medical does

terraplasma medical GmbH is a privately held German medical device company founded in 2016 and headquartered in Garching bei München. The company develops and commercializes portable cold atmospheric plasma (CAP) medical devices built around its core plasma care® platform, which generates a partially ionized gas from ambient air at room temperature. The technology is described as lethal to bacteria (including multi-resistant pathogens), viruses, fungi, and spores, while stimulating proliferation in healthy human cells to support wound healing, with no known side effects or resistance development. Its product ecosystem includes the core plasma care® device, the dermatology-specialized plasma derma care® configuration, the podo Spacer® accessory for forefoot/nail fungus application, and the plasmapax® variant positioned for the U.S. market.

The company's commercial offering spans three indication areas — wound treatment, dermatology, and podiatry — and is sold to healthcare professionals (clinics, wound managers, nursing services), dermatologists, podologists, and indirectly to patients routed through partner practitioners. In Germany, cold plasma treatment has been part of specialist dermatology training since 2021, supporting clinical adoption. The plasma care® device is CE-certified for European commercial use; the company is actively pursuing FDA clearance to enter the United States, supported by an October 2025 strategic investment and distribution partnership with BioLab Holdings, Inc. (Phoenix, USA).

terraplasma medical generates revenue primarily through hardware sales of the plasma care® device system and related accessories to clinical buyers, supplemented by a specialist partner/distributor channel and a patient-facing inquiry portal. Pricing is not publicly disclosed. The company has reported over 100,000 treatments globally using its technology, indicating an established but still early-stage commercial footprint. Management consists of Managing Directors Jens Kirsch and Dr. Christian Zschocke, with Fabian von Kuenheim serving as Chairman.

Name

terraplasma medical

Legal name

terraplasma medical GmbH

Website

https://terraplasma-medical.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

terraplasma medical GmbH is a German medtech company developing portable cold atmospheric plasma medical devices (plasma care®, plasmapax®) for wound care, dermatology, and podiatry, serving clinics, specialists, and patients across Europe and pursuing U.S. expansion.

Ownership category

akta.pro rank

Headquarters

HQ city

Garching Bei München

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. plasma care® Medical Device Sales: Sale of the plasma care® cold atmospheric plasma device system to healthcare professionals (clinics, wound managers, podologists, dermatologists) and indirectly to patients via healthcare providers. The device is CE-certified and represents the primary revenue-generating product line.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

terraplasma medical develops and manufactures portable medical devices that generate cold atmospheric plasma (CAP) from ambient air at room temperature for antimicrobial treatment. The plasma care® device system inactivates bacteria (including multi-resistant pathogens), viruses, fungi, and spores while stimulating wound healing in healthy tissue. The technology is commercialized for wound care, dermatology, and podiatry applications and is CE-certified as a medical device.

Product overview

terraplasma medical offers the plasma care® product line consisting of portable cold atmospheric plasma (CAP) medical devices. The core product plasma care® generates CAP from ambient air for antimicrobial treatment across wound care, dermatology, and podiatry applications. The ecosystem includes specialized accessories: podo Spacer® for targeted forefoot/nail fungus treatment, and plasma derma care® configuration for dermatological use. All devices are CE-certified medical products designed for both professional (HCP) and patient use.

Differentiator

Problem solved

Functional benefit

Brands

• plasma care®: Portable cold atmospheric plasma medical device for wound treatment, dermatology, and podiatry.
• plasma derma care®
• podo Spacer®
• plasmapax®

Products and services

• plasma care® A portable, CE-certified medical device with the size and weight of a telephone receiver that generates cold atmospheric plasma from ambient air. It inactivates bacteria (including multi-resistant pathogens), viruses, fungi, and spores while promoting wound healing, and is sold to healthcare professionals such as clinics, wound managers, nursing services, dermatologists, and podologists.
• plasma derma care® A specialized variant of the plasma care® system configured for dermatological use, targeting inflammatory skin conditions such as acne, actinic keratosis, neurodermatitis, and viral diseases such as herpes. It includes a skin-friendly, flexible foam attachment designed for uneven skin surfaces and the facial region.
• plasmapax® Portable cold atmospheric plasma (CAP) technology device commercialized in partnership with BioLab Holdings for the U.S. wound care, dermatology, and podiatry markets, currently pursuing FDA clearance.

Quantifiable outcome

• Inactivates bacteria, viruses, fungi, spores, and multi-resistant pathogens (MRE) through cold atmospheric plasma; activates wound healing and cell proliferation; treatment area of 78 cm² per spacer; pain-free application with no known allergies or side effects.

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• BioLab Holdings, Inc.coreStrategic or Co-development Partner · 24 October 2025BioLab Holdings, Inc., a Phoenix-based medical manufacturer, announced a strategic investment and partnership with terraplasma medical GmbH to commercialize the plasmapax® cold atmospheric plasma device in the U.S. market. The partnership aims to expand access to the U.S. market for terraplasma's device, which has already been used in over 100,000 treatments globally. terraplasma medical is pursuing FDA clearance with BioLab providing its established distribution network and commercialization infrastructure.
• BioLab Holdings, Inc.coreStrategic or Co-development Partner · 24 October 2025BioLab Holdings' investment and partnership with terraplasma medical targets the U.S. wound care, dermatology, and podiatry markets. terraplasma medical brings its FDA-clearance-seeking plasmapax® device while BioLab provides its distribution network for market expansion in the United States.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Ethicon (Johnson & Johnson MedTech): Major surgical wound closure and biosurgery business within J&J MedTech, supplying sutures, topical hemostats, and surgical infection prevention products. Comparable as an incumbent serving surgical wound care and skin-related surgical applications where post-surgical infection prevention is a key value proposition of cold plasma therapy.
• Smith & Nephew: Global medical device company with a leading advanced wound management portfolio serving hospitals, clinics, and home-care settings. Comparable as a large incumbent in wound care — the primary indication terraplasma's plasma care® device addresses — with established clinical evidence and reimbursement infrastructure.
• ConvaTec: UK-headquartered global medical products company with a strong advanced wound care franchise (AQUACEL, Foam dressings) and an ostomy care business. Comparable as a wound-care incumbent serving the same clinical specialties (wound management, dermatology-adjacent indications) targeted by terraplasma.
• 3M Health Care: Major medical device and consumer health company with a substantial wound care and skin health portfolio (including Acelity/KCI assets). Comparable as a large healthcare incumbent in advanced wound care whose commercial scale and U.S. distribution depth would be a benchmark for any wound-care entrant.
• Coloplast: Danish medical device company with a leading wound care and skin care business alongside ostomy and continence care. Comparable as a European medtech incumbent with established clinical channels in the same specialty practices (wound, dermatology, podiatry nursing) where plasma care® is being adopted.
• Mölnlycke Health Care: Swedish-headquartered global leader in wound care and surgical solutions, including Mepilex, Mepitel, and other advanced wound dressings. Comparable as a dominant wound-care incumbent whose hospital channel and clinical-evidence base could both enable and compete with cold plasma therapy adoption.
• Cynosure (Hologic): U.S.-based aesthetic and dermatology device company owned by Hologic, offering energy-based devices (laser, RF) for skin conditions and aesthetic practices. Comparable as a broader dermatology-focused device maker whose U.S. aesthetics and dermatology channels represent a potential distribution complement and competitive reference point.
• Erbe Elektromedizin: German manufacturer of electrosurgery and plasma-based surgical devices used in operating rooms and clinics globally. Comparable as a German medtech incumbent using plasma technology in clinical/therapeutic applications, though Erbe specializes in surgical instrumentation rather than CAP wound therapy.

Direct peers

• neoplas med GmbH: German medical device company developing cold atmospheric plasma (kINPen med) for wound healing, dermatology, and other medical indications. The closest direct peer — both companies are German-based CAP medical device specialists with CE-marked products targeting overlapping indications including chronic wound care and dermatology.

Emerging players

• Plasma Surgical: U.S./UK-based medical device company developing neutral plasma surgery technology (PlasmaJet) for surgical applications including oncology and wound care. Comparable as a plasma-based medical device competitor in adjacent clinical use cases; smaller scale than broad incumbents but operating in the same plasma-medicine technology category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/terraplasma-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about terraplasma medical